Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial

Yao-Chun Hsu, Chi-Yi Chen, Cheng-Hao Tseng, Chieh-Chang Chen, Teng-Yu Lee, Ming-Jong Bair, Jyh-Jou Chen, Yen-Tsung Huang, I-Wei Chang, Chi-Yang Chang, Chun-Ying Wu, Ming-Shiang Wu, Lein-Ray Mo, Jaw-Town Lin

Clin Mol Hepatol. 2025;31(1):213-226. Published online October 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0640

View: 883 Download: 122

Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients

Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, Wen-Juei Jeng, Wei-Wen Su, Ting-Tsung Chang, Chi-Yi Chen, Yao-Chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L. Conery

Clin Mol Hepatol. 2024;30(3):375-387. Published online March 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0535

View: 3275 Download: 119 Web of Science: 1 Crossref: 1

Correspondence

Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring

Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu

Clin Mol Hepatol. 2024;30(2):293-296. Published online February 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0101

View: 2033 Download: 66

Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research

Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu

Clin Mol Hepatol. 2024;30(2):276-278. Published online April 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0220

View: 2289 Download: 41

Original Article

Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation

Ying-Nan Tsai, Jia-Ling Wu, Cheng-Hao Tseng, Tzu-Haw Chen, Yi-Ling Wu, Chieh-Chang Chen, Yu-Jen Fang, Tzeng-Huey Yang, Mindie H. Nguyen, Jaw-Town Lin, Yao-Chun Hsu

Clin Mol Hepatol. 2024;30(1):98-108. Published online December 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0194

View: 3070 Download: 185 Web of Science: 6 Crossref: 10

Review

Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm

Yao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao

Clin Mol Hepatol. 2023;29(4):869-890. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2022.0420

View: 4395 Download: 221 Web of Science: 7 Crossref: 12

Correspondence

Expanding Treatment Eligibility for Chronic Hepatitis B: Balancing Benefits, Limitations, and Healthcare Access

Yao-Chun Hsu, Chi-Yi Chen, Jaw-Town Lin

Received December 16, 2024 Accepted December 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.1138 [Accepted]

View: 240 Download: 12

1 |

Viewed By 5975	MAFLD: How is it different from NAFLD?
Viewed By 4882	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4628	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 3442	Gut microbiome and metabolome signatures in liver cirrhosis-related complications
Viewed By 2908	Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis

Cited By 283	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 234	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 157	MAFLD: How is it different from NAFLD?
Cited By 82	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 76	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search